The acquisition of Creoptix AG, a specialist bioanalysis sensor company, enables Malvern Panalytical to expand its capabilities in support of drug discovery. The latter provides advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries.
Creoptix focuses on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research. Its proprietary sensor and microfluidics technology, the Creoptix WAVEsystem offers a breakthrough level of kinetics analysis. Engineered around their proprietary Grating-Coupled Interferometry (GCI) technology, these tools enable researchers to access high-quality binding affinity and kinetics data across a broader range of samples than traditional SPR-based solutions. Creoptix’s solutions help its pharmaceutical/life sciences customers accelerate the discovery and development of new drug products.
During the first half of 2022, Malvern Panalytical, a Worcestershire (England) based company with 2200 employees, will complete the integration of Creoptix into its company. This move comes after the acquisition of the startup to help Malvern expand its pharmaceutical drug development solutions. Malvern provides instruments that combine cutting edge engineering with the latest developments in data analytics and AI, these allow industries and researchers to understand the world with absolute precision, from biomolecular structures to quantum dots.
“We are really excited to welcome the Creoptix team into the Malvern Panalytical family’, stated Mark Fleiner, President of Malvern Panalytical. “We have always been driven by our desire to support our customers in the development of ground-breaking new drug products. Creoptix significantly builds on the instrumentation and services capabilities we have to achieve this, strengthening our position in supporting small molecule pharmaceutical development, while also significantly growing our capabilities in the fast-growing biopharmaceutical space.”
Line Stigen Raquet, CEO Creoptix, also sees significant opportunities resulting from joining the Malvern Panalytical team. “The purpose of Creoptix has always been to enable life scientists to accelerate drug discovery”, said Line. “Our WAVE portfolio is designed with the vision to advance breakthrough science, and to help scientists develop new and better drugs, faster. We believe that this is an exciting opportunity to further accelerate and deliver on our purpose, as we benefit from the exceptional knowledge and global customer reach provided by Malvern Panalytical.”
Founded in 2009, Creoptic is headquartered in Wädenswil, near Zurich with a US office in the Boston area. The company has completed several financing rounds with Eduard Brunner from Start Angels Network, Privilège Ventures and Swisscanto (CH) Private Equity Switzerland Growth I Fund, respectively, as lead investors.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines